Concepedia

Michael Derks

MD

Statistics

Publications

14

Citations

418

H-Index

13

Active since

1988

Affiliations

Roche (Switzerland)(Current)

Roche (United Kingdom)

Michael Derks is an author at Roche (Switzerland) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

1988–2022

14

Publications

14

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Federico Bolognani, Marta del Valle Rubido, Lisa Squassante et al. · Science Translational Medicine · 2019 · 127 citations

Medicine, Pharmacology, Pharmacotherapy +15

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Celia Goeldner, Priya S. Kishnani, Brian G. Skotko et al. · Journal of Neurodevelopmental Disorders · 2022 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man

Joerg F. Hipp, Frédéric Knoflach, Robert A. Comley et al. · Scientific Reports · 2021 · 39 citations · Full text

Medicine, Neuroscience, Pharmacology +15

Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug‐Drug Interactions

Michael Derks, Markus Abt, Mary C. Phelan et al. · The Journal of Clinical Pharmacology · 2010 · 24 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib

Michael Derks, Stephen Fowler, Olaf Kuhlmann · Clinical Therapeutics · 2009 · 24 citations

Medicine, Pharmacokinetics, Pharmacology +13

1–5 of 14